<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2976-0526</journal-id>
<journal-title><![CDATA[Portuguese Kidney Journal (PKJ)]]></journal-title>
<abbrev-journal-title><![CDATA[PKJ]]></abbrev-journal-title>
<issn>2976-0526</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Nefrologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2976-05262025000100044</article-id>
<article-id pub-id-type="doi">10.71749/pkj.52</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[C3 Glomerulonephritis: From Diagnosis to Management in a Unique Patient Case]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[Nuno]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[Rui]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Unidade Local de Saúde de Coimbra Hospitais da Universidade de Coimbra Nephrology Service]]></institution>
<addr-line><![CDATA[Coimbra ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<volume>39</volume>
<numero>1</numero>
<fpage>44</fpage>
<lpage>48</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2976-05262025000100044&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2976-05262025000100044&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2976-05262025000100044&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract C3 glomerulopathies (C3G) are ultra&#8209;rare diseases driven by dysregulation of the alternative pathway in the complement system, leading to glomerular C3 deposition and inflammation. C3G includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), both associated with progression to end&#8209;stage renal disease (ESRD). This report presents a C3GN case, highlighting diagnostic and therapeutic complexities. A 19&#8209;year&#8209;old male with recurrent macroscopic hematuria triggered by respiratory infections was initially managed for suspected IgA nephropathy. Follow&#8209;up revealed persistent low serum C3 levels, prompting a kidney biopsy that confirmed C3GN with a membranoproliferative pattern and dominant C3 deposits. Genetic testing revealed a C3 mutation and positive anti&#8209;Factor H antibodies. Despite treatment with renin&#8209;angiotensin&#8209;aldosterone system blockade, steroids, and mycophenolate mofetil (MMF), the patient&#8217;s proteinuria fluctuated, requiring adjustments in immunosuppressive therapy. C3GN can mimic other glomerulonephritides such as IgA nephropathy and atypical hemolytic uremic syndrome (aHUS). Accurate diagnosis relies on kidney biopsy findings and complement studies; genetic testing can provide critical insights. While available therapies, including immunosuppressants and complement inhibitors, offer partial benefit, C3GN often progresses, underscoring the need for novel, more effective treatments. This case illustrates the diagnostic challenges of C3GN in patients with hypocomplementemia and recurrent hematuria. It emphasizes the importance of targeted research into complement therapies to potentially improve outcomes for C3G.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Complement C3]]></kwd>
<kwd lng="en"><![CDATA[Glomerulonephritis]]></kwd>
<kwd lng="en"><![CDATA[Glomerulonephritis, Membranoproliferative]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fakhouri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Frémeaux-Bacchi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Noël]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Pickering]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[C3 glomerulopathy a new classification]]></article-title>
<source><![CDATA[Nat Rev Nephrol]]></source>
<year>2010</year>
<volume>6</volume>
<page-range>494-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Durey]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Sinha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Togarsimalemath]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Bagga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-complement -factor H -associated glomerulopathies]]></article-title>
<source><![CDATA[Nat Rev Nephrol]]></source>
<year>2016</year>
<volume>12</volume>
<page-range>563-78</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodship]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Fakhouri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fervenza]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Frémeaux-Bacchi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kavanagh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atypical hemolytic uremic syndrome and C3 glomerulopathy conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2017</year>
<volume>91</volume>
<page-range>539-51</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feehaly]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Floege]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tonelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Comprehensive Clinical Nephrology]]></source>
<year>2019</year>
<edition>6</edition>
<publisher-loc><![CDATA[Amsterdam ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rabasco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cavero]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Román]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of mycophenolate mofetil in C3 glomerulonephritis]]></article-title>
<collab>Rojas -Rivera J.Olea T.Espinosa M</collab>
<source><![CDATA[Kidney Int]]></source>
<year>2015</year>
<volume>88</volume>
<page-range>1153-60</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Avasare]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Canetta]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Bomback]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Marasa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Caliskan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ozluk]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy A Case Series]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2018</year>
<volume>13</volume>
<page-range>406-13</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giaime]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Daniel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Burtey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy]]></article-title>
<source><![CDATA[Clin Nephrol]]></source>
<year>2015</year>
<volume>83</volume>
<page-range>57-60</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Servais]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary glomerulonephritis with isolated C3 deposits a new entity which shares common genetic risk factors with haemolytic uraemic syndrome]]></article-title>
<collab>Frémeaux -Bacchi V.Lequintrec M.Salomon R.Blouin J.Knebelmann B</collab>
<source><![CDATA[J Med Genet]]></source>
<year>2007</year>
<volume>44</volume>
<page-range>193-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pickering]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[C3 glomerulopathy consensus report]]></article-title>
<collab>D'Agati VD.Nester CM.Smith RJ.Haas M.Ap-pel GB</collab>
<source><![CDATA[Kidney Int]]></source>
<year>2013</year>
<volume>84</volume>
<page-range>1079-89</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bomback]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Appel]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathogenesis of the C3 glomerulopathies and reclassification of MPGN]]></article-title>
<source><![CDATA[Nat Rev Nephrol]]></source>
<year>2012</year>
<volume>8</volume>
<page-range>634-42</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<collab>Medjeral -Thomas NR.O'Shaughnessy MM.O'Regan JA.Traynor C.Flanagan M.Wong L</collab>
<article-title xml:lang=""><![CDATA[C3 glomerulopathy clinicopathologic features and predictors of outcome]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2014</year>
<volume>9</volume>
<page-range>46-53</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<collab>Martínez -Barricarte R.Heurich M.Valdes -Cañedo F.Vazquez -Martul E.Torreira E.Montes T</collab>
<article-title xml:lang=""><![CDATA[Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>2010</year>
<volume>120</volume>
<page-range>3702-12</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Frees]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Causes of alternative pathway dysregulation in dense deposit disease]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2012</year>
<volume>7</volume>
<page-range>265-74</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Pickering]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dense deposit dis-ease]]></article-title>
<source><![CDATA[Mol Immunol]]></source>
<year>2011</year>
<volume>48</volume>
<page-range>1604-10</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le Quintrec]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lapeyraque]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Lionet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy]]></article-title>
<collab>Sellier -Leclerc AL.Delmas Y.Baudouin V</collab>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2018</year>
<volume>72</volume>
<page-range>84-92</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bomback]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Barile]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Heher]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Herlitz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab for dense deposit disease and C3 glomerulonephritis]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2012</year>
<volume>7</volume>
<page-range>748-56</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nester]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment options for C3 glomerulopathy]]></article-title>
<source><![CDATA[Curr Opin Nephrol Hypertens]]></source>
<year>2013</year>
<volume>22</volume>
<page-range>231-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nester]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cavero]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Karras]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Le Quintrec]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Light-stone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy]]></article-title>
<source><![CDATA[Kidney Int Rep]]></source>
<year>2023</year>
<volume>8</volume>
<page-range>2754-64</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
